Dermatology

Nutritional and microbial strategies are emerging as pivotal in treating skin conditions such as acne, alopecia, and atopic dermatitis.

Nearly half of patients with metastatic melanoma treated with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab have survived cancer-free, underscoring the impact of immunotherapy in advanced melanoma.

A major randomized clinical trial has demonstrated that home-based narrowband UV-B phototherapy is as effective as office-based treatment for patients with plaque or guttate psoriasis.

A clinical trial has shown that dupilumab, a monoclonal antibody targeting IL-4 and IL-13, may offer benefits to patients in managing bullous pemphigoid, a rare autoimmune blistering disease.

A strong link between childhood obesity and the development of immune-mediated skin diseases has been highlighted in new research.   

Approval has been granted by the FDA for lebrikizumab-lbkz in treating moderate to severe atopic dermatitis in patients aged 12 and older.

Gaps in dermatology education have been spotlighted in preclinical medical students.

The UNCOVER-3 trial is a recent study that has demonstrated that ixekizumab, a biologic treatment for moderate-to-severe plaque psoriasis, is effective in managing psoriasis across challenging body areas including the scalp, face, palmoplantar surfaces, or nails.